REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
03/14/2026
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Quick snapshot
HUMABODY
ST13
US500000079179556Class
Filing
Registration
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Case type
Recorded events
Latest update
Classification
Trademark type
Nice classes
Filing date
Registration date
Expiration date
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Structured fields from the responsible authority and the official record.
Status date
Last transaction
Responsible office
Status code
Official register
Drawing code
Owner type
Owner location
Examiner
Current location
Holders
Representatives
Rebecca Liebowitz VENABLE LLP
Nice Classes
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
chemicals used in industry and science; [ chemical test kits for in vitro testing for laboratory research purposes; ] biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for in vitro scientific and laboratory research use; biochemicals, namely, monoclonal antibodies and antibody fragments for in vitro scientific and laboratory research use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products
Class 5
pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; veterinary preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; antibody fragments being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases] ; antibody therapeutics in the nature of therapeutic agents for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; medical diagnostic reagents and veterinary diagnostic reagents in the nature of antibodies and antibody fragments; antibodies and antibody fragments being therapeutic pharmaceuticals for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] and or use in the manufacture of therapeutic products
Class 40
[ Treatment and transformation of materials for others, namely, the manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; custom manufacture of therapies using antibodies and antibody fragments ]
Class 42
[ Scientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; Scientific laboratory services in the field of antibodies and antibody fragments; research in the field of the development of antibodies and antibody fragments; provision of scientific information in the field of antibodies and antibody fragments for medical and veterinary purposes; engineering of antibodies and antibody fragments; scientific services, namely, drug discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, consulting in the field of antibody and antibody fragment design ]
History of USPTO decisions and trademark events.
55 publications found
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
03/14/2026
PARTIAL INVALIDATION PROCESSED BY THE IB
06/20/2025
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
05/12/2025
INVALIDATION PROCESSED
05/12/2025
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
05/12/2025
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
02/27/2025
INTERNATIONAL REGISTRATION RENEWED
12/12/2024
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
11/08/2024
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
06/27/2024
REGISTERED - PARTIAL SEC 71 ACCEPTED
06/27/2024
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/07/2024
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
10/27/2023
TEAS SECTION 71 RECEIVED
09/13/2023
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
08/19/2023
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
03/14/2022
NEW REPRESENTATIVE AT IB RECEIVED
12/07/2017
FINAL DECISION TRANSACTION PROCESSED BY IB
07/14/2017
FINAL DISPOSITION NOTICE SENT TO IB
06/22/2017
FINAL DISPOSITION PROCESSED
06/22/2017
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/14/2017
REGISTERED-PRINCIPAL REGISTER
03/14/2017
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
02/03/2017
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
11/18/2016
EXTENSION OF TIME TO OPPOSE RECEIVED
10/18/2016
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/20/2016
PUBLISHED FOR OPPOSITION
09/20/2016
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/31/2016
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/31/2016
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/31/2016
LAW OFFICE PUBLICATION REVIEW COMPLETED
08/17/2016
APPROVED FOR PUB - PRINCIPAL REGISTER
08/09/2016
EXAMINER'S AMENDMENT ENTERED
08/09/2016
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/09/2016
EXAMINERS AMENDMENT E-MAILED
08/09/2016
EXAMINERS AMENDMENT -WRITTEN
08/09/2016
TEAS/EMAIL CORRESPONDENCE ENTERED
08/08/2016
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/08/2016
TEAS REQUEST FOR RECONSIDERATION RECEIVED
08/08/2016
NOTIFICATION OF FINAL REFUSAL EMAILED
07/29/2016
FINAL REFUSAL E-MAILED
07/29/2016
FINAL REFUSAL WRITTEN
07/29/2016
TEAS/EMAIL CORRESPONDENCE ENTERED
07/15/2016
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/15/2016
ASSIGNED TO LIE
07/15/2016
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/11/2016
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/11/2016
REFUSAL PROCESSED BY IB
02/01/2016
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/11/2016
REFUSAL PROCESSED BY MPU
01/11/2016
APPLICATION FILING RECEIPT MAILED
01/08/2016
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/06/2016
NON-FINAL ACTION WRITTEN
01/05/2016
ASSIGNED TO EXAMINER
01/04/2016
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/04/2016
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/03/2016
Continuous trademark protection
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.